177Lu-FAP-2286 followed by low-dose chemotherapy significantly reduced mediastinal mass intensity and relieved acute superior vena cava syndrome in a patient with thymus squamous carcinoma.
Does 177Lu-FAP-2286 treatment followed by low-dose chemotherapy reduce mediastinal mass intensity and relieve superior vena cava syndrome in a patient with thymus nonkeratinized squamous carcinoma?
177Lu-FAP-2286 combined with low-dose chemotherapy successfully reduced tumor burden and relieved superior vena cava syndrome in a patient with thymus nonkeratinizing squamous carcinoma.
Absolute Event Rate: 0% vs 0%
We reported a 52-year-old man with thymus nonkeratinized squamous carcinoma presenting with acute superior vena cava syndrome (SVCS) who received 177 Lu-FAP-2286 treatment and followed by low-dose chemotherapy. 68 Ga-FAP-2286 PET/CT revealed significantly less intensity of the mediastinal mass comparing to pretherapy scan, as well as significant relief of SVCS. No adverse effects were observed.
Deng et al. (Tue,) reported a other. 177Lu-FAP-2286 followed by low-dose chemotherapy significantly reduced mediastinal mass intensity and relieved acute superior vena cava syndrome in a patient with thymus squamous carcinoma.